Xilio Therapeutics Enhances Board with Two New Directors
PremiumCompany AnnouncementsXilio Therapeutics Enhances Board with Two New Directors
5M ago
Xilio Therapeutics expects cash to fund operations into Q2 of 2025
Premium
The Fly
Xilio Therapeutics expects cash to fund operations into Q2 of 2025
6M ago
Xilio Therapeutics reports Q1 EPS (62c) vs (83c) last year
Premium
The Fly
Xilio Therapeutics reports Q1 EPS (62c) vs (83c) last year
6M ago
Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
PremiumThe FlyGilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
7M ago
Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
Premium
The Fly
Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
7M ago
Xilio Therapeutics announces $11.3M private placement equity financing
Premium
The Fly
Xilio Therapeutics announces $11.3M private placement equity financing
7M ago
Xilio Therapeutics price target lowered to $6 from $9 at Guggenheim
PremiumThe FlyXilio Therapeutics price target lowered to $6 from $9 at Guggenheim
1y ago
Xilio reports initial monotherapy safety and anti-tumor activity data for XTX202
Premium
The Fly
Xilio reports initial monotherapy safety and anti-tumor activity data for XTX202
1y ago
Xilio Therapeutics promotes Katarina Luptakova to CMO, Scott Coleman to CDO
Premium
The Fly
Xilio Therapeutics promotes Katarina Luptakova to CMO, Scott Coleman to CDO
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100